Follow-up Study of ICUS and CCUS Patients
NCT04428489 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2025-12-29
Summary
The proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions has been released by an international consensus group. Based on the criteria, patients with persistent cytopenia could be diagnosed with MDS, CCUS and ICUS. However, the process and outcome of pre-MDS conditions (CCUS, ICUS) is still to be characterized in Chinese population. We design this prospective observational study to explore the disease process and outcome in ICUS and CCUS patients.
Conditions
Interventions
- OTHER
-
Observation and necessary supportive care
For patients with ICUS and CCUS, necessary supportive care could be given. No addtitional treatment is administrated.
Sponsors & Collaborators
-
The First Affiliated Hospital of Soochow University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-01-01
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent
NCT03045510 ·Status: UNKNOWN ·Phase: PHASE2
-
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT05674539 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NCT04587856 ·Status: RECRUITING ·Phase: NA
-
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
NCT01929408 ·Status: COMPLETED
-
Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia
NCT02344966 ·Status: UNKNOWN
-
Medium Dose of Cytarabine and Mitoxantrone
NCT04024241 ·Status: UNKNOWN
-
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
NCT00774046 ·Status: COMPLETED ·Phase: PHASE2
-
RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT
NCT03412266 ·Status: UNKNOWN ·Phase: PHASE2
-
Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms
NCT04460950 ·Status: RECRUITING
-
M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia
NCT05739630 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
NCT04446806 ·Status: UNKNOWN ·Phase: PHASE4
-
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes
NCT06581055 ·Status: WITHDRAWN
-
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
NCT01835587 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes
NCT02619565 ·Status: COMPLETED ·Phase: NA
-
the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient
NCT01766375 ·Status: UNKNOWN ·Phase: PHASE3
-
Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia
NCT01457040 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Clinical and Genomic Registry of MDS in Asia
NCT03169296 ·Status: UNKNOWN
-
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
NCT02474290 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study on High-risk MDS Patients Based on RNA-seq Technology
NCT03903055 ·Status: UNKNOWN
-
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
NCT01471444 ·Status: COMPLETED ·Phase: PHASE3
-
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
NCT04620681 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
NCT01041443 ·Status: COMPLETED ·Phase: PHASE1
-
HCT With PTCy in Higher-risk MDS
NCT06098313 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Efficacy of Allo-HSCT in ND HR-CBF-AML
NCT06458244 ·Status: RECRUITING
-
Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT
NCT03530085 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3